logo
Canada's top scientist releases new UFO report, here's what you need to know

Canada's top scientist releases new UFO report, here's what you need to know

CTV News14-07-2025
The Canadian government's top scientist has released a new report on unidentified flying objects.
Published Monday, the report from the Office of the Chief Science Advisor of Canada recommends the creation of a new federal body to standardize, collect and investigate UFO reports.
'The mystery of unidentified phenomena in the sky has long fascinated humanity, capturing the public imagination and arousing both skepticism and curiosity,' the new report states. 'Together, the analysis presented in this report suggests that Canada would benefit from an improved process for reporting, collecting, and studying UAP sightings.'
The acronym UAP stands for 'unidentified aerial (or anomalous) phenomena,' which has largely replaced the terms 'UFO' and 'unidentified flying objects' in official circles. After decades of dismissal and denials, the unusual subject has become the focus of recent investigations by both the Pentagon and NASA.
Known as the Sky Canada Project, the Office of the Chief Science Advisor of Canada launched its UAP research effort in 2022 and released a preliminary report in January. Cardiovascular scientist Dr. Mona Nemer has been Canada's chief science advisor since the role was created in 2017.
Tasked with providing impartial scientific advice to the government, Nemer reports directly to the prime minister and minister of innovation, science and industry.
'Our goal was to find the current resources and processes in place for handling and following up on UAP reports, to compare them with the best practices in other countries, and to make recommendations for potential improvements,' Nemer said in the new report's introduction. 'The preparation of this report has garnered more public anticipation than any project in the history of this office.'
Nemer
Dr. Mona Nemer was introduced as Canada's new Chief Science Advisor on Parliament Hill in Ottawa on Tuesday, Sept.26, 2017. THE CANADIAN PRESS/Sean Kilpatrick
CTVNews.ca was provided an advance copy of the latest Sky Canada Project report, which has been titled 'Management of Public Reporting of Unidentified Aerial Phenomena in Canada.'
From the report's recommendations to Canada's history of investigating UAP, here are five key takeaways:
It's time for Canada to investigate UAP reports
The report urges Canada to 'establish a dedicated service' to standardize, collect and investigate UAP reports.
'A federal department or agency responsible for managing public UAP data should be identified,' the report recommends. 'This service would collect testimonies, investigate cases and post its analyses publicly.'
The report specifically points to the Canadian Space Agency as a 'trusted' scientific organization that could lead this new effort in collaboration with government and academic partners. It also says Canadian aviation officials should do more when flight crews file UAP reports.
'Transport Canada should encourage pilots, cabin crews and air traffic controllers to report UAP sightings without fear of stigmatization,' the report advised.
Other recommendations include combatting disinformation, making UAP records available to the public and creating tools for data collection, like a bilingual reporting app.
'Improved data from public reports will enable more comprehensive and accurate research analyses,' the report said. 'Investigating UAP reports may also enhance airspace security by identifying threats, thus strengthening national security through the proactive mitigation of risks from UAPs.'
It remains to be seen if the federal government will implement any of the Sky Canada Project's recommendations.
In a previous statement, a CSA spokesperson told CTVNews.ca that the 'study of UAPs does not fall within the CSA's mandate and there are currently no plans to explore the topic in the future.' A Transport Canada spokesperson previously told CTVNews.ca that the department is awaiting 'concrete recommendations' and 'will carefully review the findings of the final report once published.'
'The Sky Canada Project recommendations provide a realistic framework for the consistent and efficient management of UAP sightings in Canada,' Nemer said in a statement to CTVNews.ca. 'I am confident that our leaders will take these recommendations seriously.'
Credible UAP reports are often overlooked
The Sky Canada Project flagged several government departments and agencies that routinely receive UAP reports, including Transport Canada, the Department of National Defence, the Canadian Space Agency and the Royal Canadian Mounted Police.
'However, few of these organizations are currently investigating these sightings unless they pertain to specific aspects of their respective mandates, such as national security, transportation safety or public safety, and those instances are fairly rare,' the new report explained.
Such UAP reports have been filed by everyone from professional pilots to police officers, soldiers and members of the public. The Sky Canada Project estimates there could be as many as 1,000 sightings per year in Canada.
'Reports from pilots, military personnel and civilians alike describe at times the sightings of strange lights, unusually moving objects, or phenomena in the sky for which no immediate explanation can be provided,' the report said. 'Reporting witnesses were often met with skepticism and ridicule, leading to negative perceptions and arbitrary judgments being cast upon them. Stigmatization can have significant consequences, such as discouraging witnesses from coming forward and hindering scientific inquiry.'
The Sky Canada Project noted that the 'type of response and the level of engagement varied from one organization to another.'
'In general, our colleagues in the federal government have been cooperative,' Nemer told CTVNews.ca. 'Unfortunately, they often had very little to share.'
This isn't the first time Canada researched UAP
The Sky Canada report shows that federal government involvement in UAP research goes back to the early 1950s with short-lived efforts like 'Project Magnet' from Transport Canada and 'Project Second Storey' from the Department of National Defence. Project Magnet was quickly shut down after garnering unwelcome attention. Project Second Story recommended ending all military UAP investigations.
In 1967, responsibility was shifted to the National Research Council of Canada, which collected UAP reports until 1995. A trove of files were eventually transferred to Library and Archives Canada in Ottawa, where an estimated 15,000 pages of documents can be perused in-person. Only about 9,500 pages have been digitized and made available online.
The report also mentions the work of Winnipeg-based writer and researcher Chris Rutkowski, who has documented tens of thousands of Canadian UAP cases over the past three decades – and who even once received reports directly from military and transportation officials.
'UAP reports are deserving of scientific study in that they represent a real phenomenon that has been witnessed by reliable and responsible observers, and are thus a part of the human experience,' Rutkowski told CTVNews.ca. 'While there have been offices dedicated to the UFO phenomenon in Canada in previous years, there currently does not appear to be any government agency, institution, or office where UAP reports are received and analysed for research.'
Other governments are investigating UAPs
If Canada adopts the Sky Canada Project's recommendations, it will be following in the footsteps of countries like the U.S., France, Chile and China, which have all created official bodies dedicated to collecting and analyzing UAP reports.
In the U.S., the Pentagon's current UAP research effort is known as the All-domain Anomaly Resolution Office (AARO), which has been releasing annual UAP reports in coordination with the U.S. Office of the Director of National Intelligence. In its 2024 report, AARO stated that 21 out of 757 cases received that year merited further analysis. The UAP topic has also been subject to a NASA investigation and U.S. congressional hearings.
Known by the French acronym GEIPAN, France's Unidentified Aerospace Phenomenon Research and Information Group has been investigating UAP cases since 1977. Operating under the umbrella of France's space agency, GEIPAN has examined more than 3,200 cases to date, including 102 that remained unidentified after investigation.
Other official UAP research efforts include the Chilean Air Force's Section for the Study of Anomalous Aerial Phenomena and a Chinese military task force.
No evidence of aliens, but…
The Sky Canada Project makes it clear that its mission was to focus on Canadian UAP reporting mechanisms and not sightings themselves.
'The project was not meant to prove or disprove the existence of extraterrestrial life or extraterrestrial visitors,' the report stated. 'The collection or analysis of first-hand data such as photos, videos or individual UAP sighting reports was not part of the project.'
From drones to balloons, satellites, meteors, flares, paper lanterns, planets, atmospheric phenomena, experimental technology and more, many UFO sightings could have ordinary or earthly explanations. But unless there is an obvious safety or security concern, there tends to be little sign of official investigation or follow-up from Canadian authorities, leaving most cases officially unexplained.
'UFOs are by their very definition unidentified but this does not imply that they are of extraterrestrial origin, that they defy natural or scientific explanation, or that they would not be identifiable with access to additional or better data and tools,' the report said. 'Nonetheless, some UAP sightings—for which data exist—remain unexplained even after investigation.'
Paul Delaney is an emeritus professor of physics and astronomy at York University in Toronto. While Delaney doubts that UAP represent extraterrestrial technology, he acknowledges that a small percentage of cases remain unexplained and are thus worthy of further investigation.
'Determining once and for all that UAP sightings are of an extraterrestrial origin or not is of deep interest to people everywhere,' Delaney, who was not involved in the report, told CTVNews.ca. 'While the overwhelming results of UAP reports turn out to have terrestrial explanations some one to two per cent remain truly unidentified and that remaining per cent needs clarity not speculation or disinformation.'
CTVNews.ca has reached out to several federal departments and agencies for comment, including the Canadian Space Agency, Transport Canada and the Department of National Defence. (This article will be updated with their responses.)
The Sky Canada Project report concluded that while most UAP cases can be explained by an investigation, 'some remain unsolved, suggesting the need for further analysis using advanced analytical tools.'
As for next steps, Nemer told CTVNews.ca that her office is focused on other priorities to support the new Carney government.
'But we'll be ready to help if the government request further advice on the implementation of some of our recommendations,' she said. 'I hope our report will be perceived as a positive contribution and will generate some improvements to the management of UAP sightings in Canada.'
More on this topic from Daniel Otis:
Journalist Daniel Otis has been investigating Canadian UAP cases for CTVNews.ca since 2022 and is listed as one of the individual experts consulted by the Sky Canada Project. You can share your interesting documents or observation with him at Daniel.Otis@bellmedia.ca.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

Globe and Mail

time15 minutes ago

  • Globe and Mail

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Wednesday, September 10, 2025 Time: 1:00 PM - 1:30 pm, Eastern Time Location: Lotte New York Palace Hotel, Holmes I - 4th Floor Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance. More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer info@ (415) 506-8462 Investor Relations Contact: Jami Taylor Investor Relations Advisor investors@ (415) 506-8462 Media Contact: Mark Corbae ICR Healthcare (203) 682-8288

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Globe and Mail

time15 minutes ago

  • Globe and Mail

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately. 'I am thrilled to welcome Ramón to the leadership team at Aligos,' said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. 'As we progress ALG-000184 through the Phase 2 B-SUPREME study, Ramón's extensive regulatory expertise will be a critical component as we think about the future of the program. His experience driving global regulatory strategies will help guide Aligos at this pivotal time.' 'I am excited to join the Aligos team as the company looks towards later-stage development,' stated Ramón Polo, MBA, PharmD, PhD, Senior Vice President, Head of Global Regulatory Affairs at Aligos. 'With my expertise leading global development and regulatory strategies at various pharma companies, I look forward to developing and implementing a comprehensive plan to aid in the continued development of ALG-000184.' Dr. Polo's diverse expertise includes leading and overseeing development teams, pharmacovigilance programs and regulatory strategies. He joins Aligos from Shionogi Inc., where he served as the Senior Vice President, Head of Global Regulatory Affairs, and focused on regulatory strategies for a number of different Therapeutic Areas, including infectious diseases. Previously, Dr. Polo was the Vice President, Head of Infectious Diseases, Vaccines & Global Public Health Regulatory Affairs at Johnson & Johnson, where he played a key role in navigating the scientific, regulatory and global rollout challenges of the largest health crisis in a century as part of Johnson & Johnson's core team for the COVID-19 vaccine. Prior to this, Dr. Polo led the development strategy of treatments for influenza, RSV and hepatitis C at Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Polo received his PharmD, Master of Science and Ph.D. in Clinical Biochemistry from the Complutense University of Madrid in Spain. He obtained his Global MBA from the IESE Business School, University of Navarra, and attended the Program for Management Development at Harvard Business School. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered 'forward-looking statements,' including without limitation, statements regarding Aligos' financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos' capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events. Aligos Therapeutics Contact Jordyn Tarazi Vice President, Investor Relations & Corporate Communications +1 (650) 910-0427 jtarazi@ Media Contact Inizio Evoke Jake Robison Vice President This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

'Not taking any chances:' Ontario researcher closes lab after premier warns to stop testing on dogs
'Not taking any chances:' Ontario researcher closes lab after premier warns to stop testing on dogs

CBC

time8 hours ago

  • CBC

'Not taking any chances:' Ontario researcher closes lab after premier warns to stop testing on dogs

Less than a week after Ontario Premier Doug Ford vowed to "start hunting down" scientists who use cats and dogs in medical testing studies, one Ottawa-based researcher says he is shutting down his lab. "It was enormously scary," said Carleton University Canada research professor Andy Adler, who closed his project lab at the university on Friday. "I talked to a number of people in the research ethics office here and I was told that the kind of stuff I'm doing is extremely non-invasive and that I shouldn't need to worry, but here's the premier of Ontario threatening to hunt me down. I was scared." Last Tuesday, Premier Doug Ford told a press conference in Windsor that it was unacceptable for canines to be used in cardiac research that was approved by London's Lawson Research Institute and St. Joseph's Health Care London. "I have now directed our team to start hunting down anyone else doing research on dogs or cats," Ford said. "If you're doing this with dogs or cats, you gotta stop before I catch you.... We're going to legislate this.... You aren't gonna be going after animals like that." A day earlier, St. Joseph's said it would immediately end all research involving dogs"following consultations with the province." Neither the hospital nor the premier's office responded to CBC' questions about whether the province directly ordered the cardiac testing to end. Adler's research lab was working on developing improved veterinary monitoring technology, meant to help veterinarians check large animals' lungs and blood flow during daily surgeries, ensuring they remain stable throughout the process. His lab was creating a new type of stick-on electrode to be used in these scenarios that can reach around animals' fur, so veterinarians will not need to shave them. "The dog market is big. There are lots of dogs and lots of dogs get surgery," Adler said. "There is a big need to have improved instruments to help to do that kind of care better." Animal testing at Adler's lab involved putting typical monitoring jackets and the newly-built electrodes on service animals working at the university, allowing researchers to compare the efficacy. He has done the exact same type of testing on horses, and similar work on dolphins and sea lions, he said. "This is very non-invasive stuff that we're doing here at Carleton," Adler said, adding he has previously done more invasive testing outside of the school that involved euthanizing dogs. Still, he said Ford's statement comes across as all-inclusive. "The premier wasn't just saying, 'If you are doing something egregious, [you will be hunted down]', but 'If you are doing any research at all on cats and dogs, you will be hunted down,'" Adler said. "This is super threatening language and is explicitly intended to cover people like me who are doing very non-invasive work. "I'm not taking any chances." The premier's office did not respond to CBC's questions about whether he plans to end all types of research or dogs and cats, or if there could be exceptions. St. Joseph's creating research 'transition plan' Lisa Porter, the scientific director and vice-president of research at Lawson, left the organization last week. St. Joseph's has refused continuous interview requests from CBC News about its canine testing research and specifics on why it ended the program. In a statement sent to staff and media on Thursday, the hospital said it is "working on a transition plan to minimize the impact on our researchers and their work, which has resulted in major strides in cardiac care and treatment." The statement also said St. Joseph's plans to appoint an independent third party to review its animal-based research and is now turning its attention to in-hospital safety. "In the coming weeks, we will continue to focus on the safety and security of our staff, physicians, researchers, patients, residents and visitors," the statement said. The hospital has refused to answer CBC's questions about whether researchers or staff have received threats and if the hospital has hired any additional security over the last week for this reason. Higher risks for young researchers Adler said on the day he shut down his lab, he destroyed all documents that could identify the student researchers who were part of his canine trials, with both their safety and careers in mind. "If I'm going to be hunted down for my crimes, I intend to do it alone," he said, adding the premier's comments could impact other masters-level researchers around the province. "Imagine a student who's put four years into their PhD and is reluctant to publish a thesis that would name them by name. Their enthusiasm for their work is now tempered by the threat." Adler said he plans to move testing for his project outside of Ontario, and potentially out of the country, in order to continue developing the important new technology. "Vets have much less technology available to them than human doctors, and they're hungrier for innovation," he said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store